Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prasugrel - Daiichi Sankyo/Eli Lilly and Company

Drug Profile

Prasugrel - Daiichi Sankyo/Eli Lilly and Company

Alternative Names: CS-747; CS-747S; Effient; Efient; LY 640315; Prasugrel-hydrochloride; R 99224

Latest Information Update: 05 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company; Ube Industries
  • Developer Daiichi Sankyo Company; Eli Lilly; Eli Lilly and Company; Kurume University; Ube Industries
  • Class Anti-ischaemics; Antiplatelets; Antithrombotics; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Sickle cell anaemia; Stroke
  • Phase II Ischaemic heart disorders

Most Recent Events

  • 25 Oct 2018 Daiichi Sankyo Company completes the phase II CONVERT 2 trial in Ischaemic heart disorders in Japan (PO) (UMIN000027089)
  • 01 Oct 2018 Daiichi Sankyo Company initiates the phase III PRASTRO-III trial for Stroke in Japan (PO) (JapicCTI-184141)
  • 25 Aug 2018 Efficacy data from the phase IV TROPICAL-ACS trial in Acute coronary syndromes presented at the Annual Congress of the European Society of Cardiology (ESC-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top